Literature DB >> 15316983

The use of statistical MUNE in a multicenter clinical trial.

J M Shefner1, M E Cudkowicz, H Zhang, D Schoenfeld, D Jillapalli.   

Abstract

Techniques to estimate motor unit number (MUNE) measure the number of functioning motor units in a muscle. In diseases characterized by progressive motor unit loss, such as amyotrophic lateral sclerosis (ALS), MUNE may be useful to monitor disease progression or beneficial response to treatment. As part of a multicenter, placebo-controlled, randomized, double-blind clinical trial testing the efficacy of creatine in patients with ALS, statistical MUNE was measured in 104 patients tested monthly for 6 months. The objective was to determine whether MUNE was a reliable and sensitive outcome measure in the context of a multicenter trial. Formal training and reliability testing was required for all MUNE evaluators. Testing of normal controls showed a high degree of test-retest reliability. All patient data were combined as the experimental treatment showed no efficacy. There was a 23% decline in MUNE over 6 months. The technique as employed in this trial overemphasized the presence of small motor units; this problem was partially addressed by poststudy data monitoring and censuring. Thus, MUNE can be used reliably as an outcome measure in multicenter clinical trials; specific remedies are suggested for the difficulties encountered in this study.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15316983     DOI: 10.1002/mus.20120

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  18 in total

Review 1.  How can we improve clinical trials in amyotrophic lateral sclerosis?

Authors:  Paul H Gordon; Vincent Meininger
Journal:  Nat Rev Neurol       Date:  2011-09-27       Impact factor: 42.937

Review 2.  Redox modifier genes and pathways in amyotrophic lateral sclerosis.

Authors:  Barrie J Carter; Pervin Anklesaria; Stephanie Choi; John F Engelhardt
Journal:  Antioxid Redox Signal       Date:  2009-07       Impact factor: 8.401

3.  Multipoint incremental motor unit number estimation as an outcome measure in ALS.

Authors:  J M Shefner; M L Watson; L Simionescu; J B Caress; T M Burns; N J Maragakis; M Benatar; W S David; K R Sharma; S B Rutkove
Journal:  Neurology       Date:  2011-06-15       Impact factor: 9.910

Review 4.  Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis.

Authors:  Seward B Rutkove
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 5.  Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?

Authors:  Katharine A Nicholson; Merit E Cudkowicz; James D Berry
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 6.  ALS biomarkers for therapy development: State of the field and future directions.

Authors:  Michael Benatar; Kevin Boylan; Andreas Jeromin; Seward B Rutkove; James Berry; Nazem Atassi; Lucie Bruijn
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

7.  Clinical features of spinal and bulbar muscular atrophy.

Authors:  Lindsay E Rhodes; Brandi K Freeman; Sungyoung Auh; Angela D Kokkinis; Alison La Pean; Cheunju Chen; Tanya J Lehky; Joseph A Shrader; Ellen W Levy; Michael Harris-Love; Nicholas A Di Prospero; Kenneth H Fischbeck
Journal:  Brain       Date:  2009-12       Impact factor: 13.501

8.  Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?

Authors:  Alexandre Henriques; Claudia Pitzer; Armin Schneider
Journal:  Front Neurosci       Date:  2010-06-11       Impact factor: 4.677

9.  Motor unit number estimation in evaluating disease progression in patients with amyotrophic lateral sclerosis.

Authors:  Suk-Won Ahn; Su-Hyun Kim; Dong-Hoon Oh; Sung-Min Kim; Kyung Seok Park; Yoon-Ho Hong; Oh-Sang Kwon; Jung-Joon Sung; Kwang-Woo Lee
Journal:  J Korean Med Sci       Date:  2010-08-14       Impact factor: 2.153

Review 10.  Assessment of Motor Units in Neuromuscular Disease.

Authors:  Robert D Henderson; Pamela A McCombe
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.